Navigation Links
Veracyte, Inc. to Host Conference Call and Webcast to Discuss Second Quarter 2014 Financial Results on August 13, 2014
Date:8/6/2014

SOUTH SAN FRANCISCO, Calif., Aug. 6, 2014 /PRNewswire/ -- Veracyte, Inc. (Nasdaq: VCYT) announced today that its second quarter 2014 financial results will be released after close of market on Wednesday, August 13, 2014.  Following the announcement, Veracyte's management will host a live conference call and webcast at 5:00 p.m. Eastern Time to discuss the company's financial results and provide a general business update.   

The live webcast and subsequent replay may be accessed by visiting Veracyte's website at http://investor.veracyte.com. Please connect to the website at least 15 minutes prior to the live webcast to ensure adequate time for any necessary software download. Alternatively, please call (855) 541-0980 (U.S.) or (970) 315-0440 (international) to listen to the live conference call. The conference ID number for the live call is 79445857. Please dial in approximately 10 minutes prior to the call. The webcast will be available on the company's website approximately two hours following completion of the call for 14 days.

About Veracyte

Veracyte (Nasdaq: VCYT) is pioneering the field of molecular cytology, focusing on genomic solutions that resolve diagnostic ambiguity and enable physicians to make more informed treatment decisions at an early stage in patient care. By improving preoperative diagnostic accuracy, the company aims to help patients avoid unnecessary invasive procedures while reducing healthcare costs. Veracyte's first commercial solution, the Afirma® Thyroid FNA Analysis, provides a comprehensive approach for assessing thyroid nodules, centered on the proprietary Gene Expression Classifier (GEC) to resolve ambiguity in diagnosis. Each year, of the more than 525,000 thyroid nodule FNAs performed in the U.S., approximately 115,000 patients undergo diagnostic thyroid surgery, with 70% to 80% of nodules proving benign and thus the surgery unnecessary. Veracyte commercially launched Afirma in January 2011. As of March 31, 2014, the company has received nearly 100,000 FNA samples for evaluation using Afirma and has performed nearly 20,000 GECs to resolve indeterminate cytopathology results. Backed by multiple, peer-reviewed, published studies and included in leading medical guidelines, Afirma is covered by Medicare and major commercial payers, which collectively represent more than 135 million covered lives. Afirma is marketed and sold through a global co-promotion agreement with Genzyme Corporation, a subsidiary of Sanofi. Veracyte intends to expand its molecular cytology franchise to other clinical areas and is in product development for its first product in pulmonology. For more information, please visit www.veracyte.com.

Veracyte, Afirma, the Veracyte logo, and the Afirma logo are trademarks of Veracyte, Inc. This press release also contains trademarks and trade names that are the property of their respective owners.

Media:
Tracy Morris
650-380-4413 
Tracy.Morris@Veracyte.com

Investors:
Angeli Kolhatkar
Burns McClellan, Inc.
212-213-0006
akolhatkar@burnsmc.com

 


'/>"/>
SOURCE Veracyte
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Veracyte, Inc. Announces Pricing of Initial Public Offering
2. Veracyte, Inc. to Announce Third Quarter 2013 Financial Results and Host Conference Call on Monday, November 25, 2013
3. Veracyte, Inc. Announces Third Quarter 2013 Financial Results
4. Thoratec Schedules First Quarter Conference Call, Webcast
5. Watson to Host Conference Call and Webcast to Discuss First Quarter 2012 Earnings
6. CVS Caremark Corporation to Hold First Quarter 2012 Conference Call
7. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
8. Austen BioInnovation Institute in Akron Attracts Nationally Known Speakers For Conference on Value-driven Engineering, April 23-24
9. Attendees Save Up To $800 on Global Healthcare Conferences in 2012 by Registering Through Global Information Inc.
10. Insmed to Host 2012 First Quarter Earnings Conference Call
11. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... 2016 According to responses from U.S. oncologists that ... of patients with non-small cell lung cancer (NSCLC), treatment decisions ... genetic mutation status. The findings of the survey were presented ... #P3.02b ) at the 2016 World Conference on Lung ... The survey results revealed an overall high rate of ...
(Date:12/7/2016)... Dec. 7, 2016 Boehringer Ingelheim today ... patients with unresectable malignant pleural mesothelioma (MPM) met ... data, presented at the 17 th IASLC ... Vienna , showed nintedanib plus pemetrexed/cisplatin demonstrated ... pemetrexed/cisplatin, with a significantly improved PFS (9.4 vs ...
(Date:12/7/2016)... YORK , December 7, 2016 ... Pharmaceuticals PLC (NASDAQ: JAZZ ), Anthera Pharmaceuticals Inc. ... DNAI ), and AveXis Inc. (NASDAQ: AVXS ... Sector Index fell roughly 37% to reach a level equal ... it is down by approximately 14% for the year, it ...
Breaking Medicine Technology:
(Date:12/7/2016)... ... , ... AlignLife clinics nationwide are giving back to their communities by collecting ... bountiful gifts wrapped tightly under a Christmas Tree. AlignLife hopes to spread the ... , In exchange for generous donations, customers will receive a gift in return. ...
(Date:12/7/2016)... ... December 07, 2016 , ... Sharon Kleyne, host of the ... and Your Health on Voice of America, declared on her radio program in November ... the fact that when these bullies attack leaders in corporate America, they are trying ...
(Date:12/7/2016)... ... , ... Delete® - Tattoo Removal and Laser Salon Offers Delightful Holiday Deals ... To 33% Off Botox® and Juvederm® Products Now Through December 31, 2016 , Delete® ... Deals on Botox® and Juvederm® just in time for the holiday party season. ...
(Date:12/7/2016)... ... 2016 , ... The medical profession is well aware that heart attacks do ... analyzing heart attacks among 138,602 people recorded a 35% higher number of heart attacks ... agree of course–no time of year is a good time for a heart attack! ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... its newest portable bioelectronic medicine device WellnessPro Plus for consumers and healthcare ... enhances the WellnessPro platform by expanding the treatment modalities available in a ...
Breaking Medicine News(10 mins):